Soo Dong Kim
Papers
3
Total Citations
27
H-Index
2
About
Dr. Soo Dong Kim is a leading urologic surgeon whose research centers on improving functional outcomes after robot-assisted laparoscopic radical prostatectomy (RALP), particularly in the domains of erectile dysfunction (ED) and urinary continence. His major contributions include landmark clinical trials evaluating once-daily phosphodiesterase-5 inhibitors for post-prostatectomy ED. His 2014 study on tadalafil 5 mg daily use demonstrated sustained efficacy and safety over a 1-year follow-up in 92 patients, establishing a key rehabilitative strategy (18 citations). More recently, his 2022 randomized, double-blind, placebo-controlled trial on udenafil 75 mg once daily provided high-level evidence for this agent in men undergoing bilateral nerve-sparing RALP (7 citations). Dr. Kim has also investigated surgical techniques to accelerate continence recovery, notably through posterior urethral reconstruction. His work directly addresses the most common quality-of-life concerns following prostate cancer surgery, offering evidence-based pharmacological and surgical solutions. By systematically evaluating both drug therapies and surgical refinements, Dr. Kim has made a lasting impact on post-prostatectomy rehabilitation protocols, helping patients regain function faster and more reliably.
Research Focus
Key Achievements
Top Papers
- 1
- 2
- 3